A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Azacitidine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 09 Oct 2017 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
- 09 Oct 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2018.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.